Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1975 Mar;55(3):579–586. doi: 10.1172/JCI107965

Bence Jones proteins and light chains of immunoglobulins. XI. A transient Bence Jones-related protein associated with corticosteroid therapy.

A Solomon, C L McLaughlin, J D Capra
PMCID: PMC301786  PMID: 803979

Abstract

Urine specimens from patients with multiple myeloma and Bence Jones proteinuria frequently contain low molecular weight proteins which correspond either to the amino-terminal, variant half (VL) or to the carboxyl-terminal, constant half (CL) of the Bence Jones protein. Analyses of urine specimens from such patients who had received high doses of corticosteroids as part of their treatment regimen revealed that concomitantly with a decrease in Bence Jones protein excretion was the appearance of a low molecular weight protein related to the Bence Jones protein but not identical to the VL or to the CL. Analyses of daily urine specimens obtained from one such patient over an extended time period revealed that a reproducible chain of events occurred during a treatment regimen which included oral administration of 75 mg of prednisone daily for 7 consecutive days. The amount of Bence Jones protein excreted decreased progressively, and by the 5th day was usually less than 10% of the pretreatment value. The urine specimen obtained on the 6th day of treatment was virtually devoid of Bence Jones protein but contained a newly appearing protein whose electrophoretic mobility was distinct from that of the Bence Jones protein or its VL or CL. Cessation of corticosteroid therapy resulted in a prompt disappearance of the new protein and in a progressive increase in the amount of Bence Jones protein excreted. The new protein was isolated from the urine of this patient and was purified for comparative studies with Bence Jones protein and with the VL and CL prepared by specific enzymatic cleavage of the Bence Jones protein. These studies revealed that the new protein was most related antigenically to the CL, but could be distinguished immunochemically from the CL. This new protein, a component found in vivo related to the constant half of the light polypeptide chain, was designated CL, and was structurally 25 amino acid residues longer than the CL, that is, the amino-terminus of the enzymatically prepared CL was at position 117 whereas that of the transitory new Bence Jones-related protein was at position 92 of the light polypeptide chain. Biosynthetic studies were performed with plasma cells derived from the bone marrow of this patient at a time when both the CL and the Bence Jones protein were being excreted; both proteins were identified in extracellular culture fluid by immunochemical techniques. Whether the CL is of synthetic or catabolic origin is presently not known; however, the detection of the CL and the absence of any detectable protein related to the VL in the extracellular culture fluid might imply a synthetic origin of the CL and suggest a corticosteroid-induced alteration in light chain synthesis.

Full text

PDF
579

Images in this article

581Image
on p.581
581Image
on p.581
582Image
on p.582
583Image
on p.583
584Image
on p.584

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexanian R., Haut A., Khan A. U., Lane M., McKelvey E. M., Migliore P. J., Stuckey W. J., Jr, Wilson H. E. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969 Jun 2;208(9):1680–1685. doi: 10.1001/jama.208.9.1680. [DOI] [PubMed] [Google Scholar]
  2. Butler W. T., Rossen R. D. Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. J Clin Invest. 1973 Oct;52(10):2629–2640. doi: 10.1172/JCI107455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Caggiano V., Cuttner J., Solomon A. Myeloma proteins, Bence Jones proteins and normal immunoglobulins in multiple myeloma. Blood. 1967 Sep;30(3):265–287. [PubMed] [Google Scholar]
  4. Cioli D., Baglioni C. Catabolic origin of a Bence Jones protein fragment. J Exp Med. 1968 Sep 1;128(3):517–532. doi: 10.1084/jem.128.3.517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cioli D., Baglioni C. Origin of structural variation in Bence Jones proteins. J Mol Biol. 1966 Jan;15(1):385–388. doi: 10.1016/s0022-2836(66)80237-1. [DOI] [PubMed] [Google Scholar]
  6. DEUTSCH H. F. Crystalline low molecular weight gamma-globulin from a human urine. Science. 1963 Aug 2;141(3579):435–436. doi: 10.1126/science.141.3579.435. [DOI] [PubMed] [Google Scholar]
  7. Deutsch H. F. Relationships of two light chain immunoglobulins isolated from the same human source (low molecular weight immunoglobins). Immunochemistry. 1965 Sep;2(3):207–218. doi: 10.1016/0019-2791(65)90002-9. [DOI] [PubMed] [Google Scholar]
  8. Glenner G. G., Terry W. D., Isersky C. Amyloidosis: its nature and pathogenesis. Semin Hematol. 1973 Jan;10(1):65–86. [PubMed] [Google Scholar]
  9. KUNKEL H. G. Zone electrophoresis. Methods Biochem Anal. 1954;1:141–170. doi: 10.1002/9780470110171.ch6. [DOI] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. Matsuoka Y., Yagi Y., Moore G. E., Pressman D. Isolation and characterization of free lambda-chain of immunoglobulin produced by an established cell line of human myeloma cell origin. II. Identity of lambda-chains in cells and in medium. J Immunol. 1969 Nov;103(5):962–969. [PubMed] [Google Scholar]
  12. McLaughlin C. L., Solomon A. A hidden antigenic site localized to the constrant region of light chains of immunoglobulins. Science. 1973 Feb 9;179(4073):580–582. doi: 10.1126/science.179.4073.580. [DOI] [PubMed] [Google Scholar]
  13. Milstein C. P., Steinberg A. G., McLaughlin C. L., Solomon A. Amino acid sequence change associated with genetic marker Inv(2) of human immunoglobulin. Nature. 1974 Mar 8;248(5444):160–161. doi: 10.1038/248160a0. [DOI] [PubMed] [Google Scholar]
  14. Poulik M. D. Gel electrophoresis in buffers containing urea. Methods Biochem Anal. 1966;14:455–495. doi: 10.1002/9780470110324.ch9. [DOI] [PubMed] [Google Scholar]
  15. Schubert D., Cohn M. Immunoglobulin biosynthesis. V. Light chain assembly. J Mol Biol. 1970 Nov 14;53(3):305–320. doi: 10.1016/0022-2836(70)90067-7. [DOI] [PubMed] [Google Scholar]
  16. Seon B. K., Grossberg A. L., Roholt O. A., Pressman D. Position of the selective peptic cleavage of a human kappa-chain between the Vk and Ck domains. J Immunol. 1973 Jul;111(1):269–271. [PubMed] [Google Scholar]
  17. Solomon A., Killander J., Grey H. M., Kunkel H. G. Low-molecular-weight proteins related to Bence Jones proteins in multiple myeloma. Science. 1966 Mar 11;151(3715):1237–1239. doi: 10.1126/science.151.3715.1237. [DOI] [PubMed] [Google Scholar]
  18. Solomon A., McLaughlin C. L. Bence Jones proteins and light chains of immunoglobulins. II. Immunochemical differentiation and classification of kappa-chains. J Exp Med. 1969 Dec 1;130(6):1295–1311. doi: 10.1084/jem.130.6.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Solomon A., McLaughlin C. L. Bence-Jones proteins and light chains of immunoglobulins. I. Formation and characterization of amino-terminal (variant) and carboxyl-terminal (constant) halves. J Biol Chem. 1969 Jun 25;244(12):3393–3404. [PubMed] [Google Scholar]
  20. Solomon A., McLaughlin C. L. Immunoglobulin disturbances and their clinical significance. Med Clin North Am. 1973 Mar;57(2):499–516. doi: 10.1016/s0025-7125(16)32294-5. [DOI] [PubMed] [Google Scholar]
  21. Solomon A., McLaughlin C. L., Steinberg A. G. Bence Jones proteins and light chains of immunoglobulins. 3. Inv antigenicity: a genetic expression with serologic dependency of the intact kappa light chain molecule. Immunochemistry. 1970 Aug;7(8):709–713. doi: 10.1016/0019-2791(70)90177-1. [DOI] [PubMed] [Google Scholar]
  22. Tan M., Epstein W. Antigenic analysis of an N-terminal fragment of a type k Bence Jones protein. J Immunol. 1967 Mar;98(3):568–575. [PubMed] [Google Scholar]
  23. Williams R. C., Jr, Pinnell S. R., Bratt G. T. Low molecular weight L-chain components related to Bence-Jones proteins. J Lab Clin Med. 1966 Jul;68(1):81–89. [PubMed] [Google Scholar]
  24. Wu T. T., Kabat E. A. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med. 1970 Aug 1;132(2):211–250. doi: 10.1084/jem.132.2.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. van Eyk H. G., Myszkowska K. On the localisation of antigenic determinants in a Bence Jones protein. Clin Chim Acta. 1967 Nov;18(2):101–106. doi: 10.1016/0009-8981(67)90141-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES